W

V | W | X

Product #

Image

Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart

SML1425   45-54W trifluoroacetate salt ≥95% (HPLC) 45-54W (Ac-KDGIVNGVKA-NH2) is a potent peptide inhibitor of α-synuclein aggregation that reduces amyloid toxicity in cells.
 
SML0717 W-13 ≥98% (HPLC) W-13 has also been shown to inhibit the transcytosis of IgA, recycling of transferrin and overall alter the endocytic pathway in Madin-Darby canine kidney cells.
W-13 is a membrane-permeable calmodulin antagonist. W-13 inhibits Ca2+-calmodulin-dependent phosphodiesterase and has been shown to inhibit the EGF-dependent activation of EGFR in N7xHERc fibroblasts.
 
W4262 1400W dihydrochloride >98%, solid 1400W dihydrochloride is a potent and selective inhibitor of inducible nitric oxide synthase (iNOS).
human ... NOS1(4842), NOS2(4843), NOS3(4846)
W1020 W146 hydrate ≥98% (HPLC) Potent S1P(1) competitive antagonist; Ki = 10-77 nM.
 
UC213 (R)-(+)-Warfarin ≥97% (HPLC) CYP1A2/3A4 substrate; anticoagulant.
human ... CYP2C9(1559)
UC214 (S)-(−)-Warfarin ≥97% (HPLC) CYP2C9 substrate; anticoagulant.
Warfarin is used to regulate and inhibit thromboembolic disorders. The CYP2C9 (cytochrome P450 family 2 subfamily C member 9) protein plays a major role in the inactivation of potent S-warfarin.
human ... CYP2C9(1559)
V4879   Wasp venom (social) from family Vespidae, subfamilies Vespinae and Polistinae    
W1895 WAY-100135 ≥98% (HPLC) WAY-100135 is a potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). It is selective over 5-HT1B, 1C, 2,α1, α2 and D2 receptors (IC50 > 1000 nM).
 
W108 WAY-100635 maleate salt powder WAY-100635 maleate salt is a highly selective 5-HT1A serotonin receptor antagonist. It has an ability to inhibit brexpiprazole, an antipsychotic drug that regulates serotonin-dopamine activity.
human ... HTR1A(3350)
W0270 WAY 161503 hydrochloride ≥98% (HPLC) The 5-HT2C receptors have been implicated in conditions including obesity, anxiety, depression, OCD, schizophrenia, migraine, nociception and erectile dysfunction.
 
PZ0322 WAY 170523 ≥98% (HPLC) WAY 170523 is a potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3), expressed in the skeleton during embryonic development, and sometimes highly overexpressed in human carcinomas and in chondrocytes and synovial cells in rheumatoid arthritis and osteoarthritis. Mutations in the MMP-13 gene has been shown to cause metaphyseal anadysplasia (MANDP). WAY 170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE (TNFα converting enzyme), respectively.
 
W1520 WAY-200070 ≥98% (HPLC) Potent, selective estrogen receptor-beta (ER-β) agonist (IC50 2.3 nM vs 155 nM for ER-α) with anxiolytic-like and antidepressant-like effects.
 
PZ0305 WAY-208466 dihydrochloride ≥98% (HPLC) WAY-208466 is a high affinity (Ki = 4.8 nM) 5-HT6 receptor agonist. In HeLa cells expressing cloned human 5-HT6, the compound induced cAMP production (EC50 = 7.3 nM; Emax = 100%). WAY-208466 increases cortical GABA levels and exhibits anxiolytic activity in rat studies.
 
W0145 WAY-213613 ≥98% (HPLC) WAY-213613 is a selective GLT-1/EAAT2 inhibitor. GLT-1, aka excitatory amino acid transporter (EAAT)2, is a glutamate transporter highly expressed in both neurons and astrocytes. Members of the EAAT family function to prevent excitotoxicity by removing glutamate from the synapse in the normal brain and may be therapeutic targets for diseases characterized by decreased glutamatergic function. WAY-213613 is a novel EAAT2 inhibitor and is more potent than the general EAAT inhibitor trans-2,4-PDC. WAY-213613 is selective for EAAT2 as compared to EAAT1 and EAAT3 in electrophysiology, glutamate uptake, and synaptosome assays. WAY-213613 is not a substrate for the transporters themselves, nor does it have activity at glutamate ionotropic or metabotropic receptors.
WAY-213613 is a selective inhibitor of the GLT-1/EAAT2 (glutamate transporter/excitatory amino acid transporter) in neurons and astrocytes. Members of the EAAT family function to moderate excitation by removing glutamate from the synapse; they may be therapeutic targets for diseases of glutamatergic function. WAY-213613 is more potent than the general EAAT inhibitor trans-2,4-PDC, and is selective for EAAT2 over EAAT1 and EAAT3 in electrophysiology, glutamate uptake, and synaptosome assays. It is neither a substrate for the transporters themselves, nor an agonist at glutamate ionotropic or metabotropic receptors.
 
PZ0257   WAY-252623 ≥98% (HPLC) WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model.
 
SML2223 WAY-267464 dihydrochloride ≥98% (HPLC) WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.
 
PZ0267 WAY-362450 ≥98% (HPLC) WAY-362450 is a potent and selective Farnesoid X receptor (FXR) agonist that lowers total plasma cholesterol (all lipoprotein species). WAY-362450 reduced the levels of high-density lipoprotein cholesterol (HDLc) in Cynomolgus monkeys, mice and hamsters. Apparently HDL lowering is achieved through increased transhepatic cholesterol efflux.
human ... NR1H4(9971)
SML0859   WDR5-0103 ≥98% (HPLC) WDR5-0103 is a WD40-repeat antagonist that binds to WDR55 central cavity. WDR5-0103 inhibits MLL1 histone methyltransferase activity in vitro through disruption of the interaction of MLL with WDR5.
 
W2895 WE-14 trifluoroacetate salt ≥98% (HPLC) WE-14 peptide is a highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1). It has been detected in vertebrate and invertebrate neurons and in vertebrate endocrine tissues, most notably in the adrenal, pituitary, and parathyroid glands, and has also been found in human and bovine gastro-entero-pancreatic tissues.
 
SML0238 WEB2086 ≥98% (HPLC) WEB2086 is a very potent, selective platelet-activating factor (PAF) antagonist (IC50 = 16 nM). WEB2086 inhibits the proliferation of tumor cells and slows tumor growth in xenograft tumor models, and has been shown to inhibit angiogenesis.
 
W4016 Wedelolactone ≥98% (HPLC), powder Wedelolactone inhibits NF-κB-mediated gene transcription in cells by blocking the phosphorylation and degradation of IκBα. Irreversible inhibitor of IKKα and β kinase activity (IC50 < 10 μM). Wedelolactone has no effects on p38 MAP kinase or Akt.
 
SML1334 WH-4-023 ≥98% (HPLC) WH-4-023 (KIN112) is a potent and selective inihbitor of the tyrosine kinases Lck and Src with IC50 values of 2 nM for Lck and 6 nM for Src. WH-4-023 is a somewhat less potent inhibitor of salt-inducible kinases (SIKs) with IC50 values of 10, 22 and 60 nM for SIK 1, 2 and 3 respectively. WH-4-023 was found to support self-renewal of naive human embryonic stem cells, in particular in combination with PD 0325901 (PZ0162), CHIR99021 (SML1046), and SB-590885 (SML0501).
WH-4-023 belongs to the Src kinase family. It stimulates apoptosis in GC-resistant T-acute lymphoblastic leukemia (T-ALL) cells.
 
SML1024   WHI-P154 ≥98% (HPLC) WHI-P154 is a specific inhibitor of JAK3 (IC50 = 1.8 μM) with no inhibitory activity against JAK1 or JAK2. WHI-P154 enhances myogenic differentiation of C2C12 mouse myoblast cells, and induces differentiation of neural progenitor cells. The compound WHI-P154 dose dependently inhibits expression of iNOS and NO production in LPS-challenged macrophages.
 
SML0760   WIKI4 ≥98% (HPLC) WIKI4 is a potent inhibitor of Wnt/β-catenin signaling with an EC50 ~ 75 nM in all cell lines tested including DLD1 colorectal cancer cells, NALM6 B cells, U2OS osteosarcoma cells, and hESCs. WIKI4 inhibits auto-ADP-ribosylation of tankyrase 2 (TNKS2) with an IC50 of 15 nM, preventing the ubiquitination and degradation of axin and thereby antagonizing Wnt signalling.
 
W103 WIN 51708 hydrate solid WIN 51708 hydrate is a non-peptide NK1 tachykinin receptor antagonist.
rat ... Tacr1(24807)
W102 (R)-(+)-WIN 55,212-2 mesylate salt ≥98% (HPLC) It is known to decrease the lipopolysaccharide mediated release of tumor necrosis factor- α and interleukin-1 in mice.
human ... CNR1(1268), CNR2(1269)
W104 WIN 62,577 solid Non-peptide NK1 tachykinin receptor antagonist.
human ... TACR1(6869)
rat ... Tacr1(24807)
SML2032 Win6mer trifluoroacetate salt ≥98% (HPLC) Win6mer is a potent and specific inhibitor of MLL1 and SETd1A histone H3 lysine 4 (H3K4) methyltransferase complexes that does not inhibit MLL2-4 or SETd1B complexes. Win6mer potently binds to WDR5 in a 310-helical conformation. It does not inhibit isolated SET domain activity.
 
SML0899   Windorphen ≥98% (HPLC) Windorphen is a selective Wnt/β-catenin signaling inhibitor acting through selective inhibition of p300, a histone acetyltransferase (HAT) that also acts as a critical coactivator of β-catenin, a transcription factor that mediates the Wnt signaling pathway involved in embryogenesis and cancer cell survival. Windorphen blocks Wnt signaling by selectively disrupting the association of p300 with the C-terminal transactivation domain of β-catenin-1. Windorphen does not inhibit the closely related CREB-binding protein (CBP). Windorphen induced apoptosis in several Wnt-dependent tumor cell lines including colon adenocarcinoma SW480and RKO and prostate cancer cell lines DU145 and PC3.
 
W2270 Wiskostatin Wiskostatin is a selective inhibitor of N-WASP, a ubiquitously expressed member of the Wiskott-Aldrich Syndrome protein (WASp) family that regulates actin polymerization. Wiskostatin inhibits actin-dependent cellular functions, including migration, transmembrane transport and phagocytosis.
 
W3020 WKYMVdM trifluoroacetate salt ≥98% (HPLC), powder WKYMVm is a very potent agonist of formyl peptide receptor members FPR1/FPR2 (EC50 1 nM) and FPRL1/FPRL2 (75 pM and 3 nM, respectively). WKYMVm stimulation of leukocytes has been shown to elevate intracellular calcium, induce chemotaxis, superoxide generation, cell killing and phagocytosis.
 
W0769 Wogonin hydrate ≥98% (HPLC), solid Wogonin is an anti-inflammatory agent and COX-2 inhibitor, which inhibits the induction of both iNOS and COX-2. Wogonin inhibits COX-2 (IC50 = 46 μM) without affecting COX-1. Wogonin inhibits iNOS induction and thus inhibts activation-induced C6 glial cell death. Specifically, Wogonin inhibits NF-kappaB-mediated iNOS induction.
 
W1628 Wortmannin from Penicillium funiculosum, ≥98% (HPLC and TLC) Wortmannin is a potent and specific phosphatidylinositol 3-kinase (PI3-K) inhibitor with an IC50 of 2-4 nM. Inhibition of PI3-K/Akt signal transduction cascade enhances the apoptotic effects of radiation or serum withdrawal and blocks the antiapoptotic effect of cytokines. Inhibition of PI3-K by wortmannin also blocks many of the short-term metabolic effects induced by insulin receptor activation.
human ... PIK3CD(5293), PIK3CG(5294), PIK3R1(5295)
W3144   Wortmannin, Ready Made Solution from Penicillium funiculosum, ≥95% (HPLC) Wortmannin is a low molecular weight; hydrophobic fungal metabolite with a sterol-like structure produced by Penicilium fumiculosum. Inhibition of PI3K/Akt signal transduction cascade by wortmannin, enhances the apoptotic effects of radiation or serum withdrawal and blocks the antiapoptotic effect of cytokines. PI3K inhibition by wortmannin also blocks many of the short-term metabolic effects induced by insulin receptor activation. Research has demonstrated that wortmannin inhibits two enzymes from mitotical division, key regulators Polo-like kinase (Plk) family, Plk1 and Plk3.
Wortmannin is a low-molecular-weight hydrophobic fungal metabolite with a sterol-like structure produced by Penicillium funiculosum. It is a selective inhibitor of phosphoinosidite 3-kinase. It interferes with Akt signal transduction cascade, enhancing the apoptotic effects of radiation or serum withdrawal and blocks the antiapoptotic effect of cytokines. Wortmannin is membrane-permeable, thus facilitating whole-cell studies of G-protein-coupled receptor and receptor tyrosine kinase signalling pathways. PI3K inhibition by wortmannin also blocks many of the short-term metabolic effects induced by insulin receptor activation. Research has demonstrated that wortmannin inhibits two mitotic enzymes, key regulators in the Polo-like kinase (Plk) family, Plk1 and Plk3.
Wortmannin possesses anti-inflammatory properties. This mold metabolite is capable of preventing an intermediate step in transcytosis. In fisher rat thyroid (FRT) cells, wortmannin helps to block bidirectional transcytosis of ricin.
human ... PIK3CD(5293), PIK3CG(5294), PIK3R1(5295)
W2020 WR-1065 ≥98% (HPLC) WR-1065 is cytoprotective cell-permeable reactive oxygen species scavenger and p53 activator and re-activator. Recently shown to have antiretroviral activity and an active metabolite of Amifostine which selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy.
WR-1065 is the active metabolite of the prodrug amifostine, generated by alkaline phosphatase. It is found to accumulate in many epithelial tissues. WR-1065 protects cellular membranes and DNA from free radical induced damage.
 
W1770 WR99210 WR99210 is a potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR), which is a major malarial drug target. It has subnanomolar potency for the wild type, double mutant and quadruple mutant dihydrofolate reductases.
 
W0519 WS-12 ≥98% (HPLC), powder WS-12 is a high-affinity, selective TRPM8 (cold menthol receptor 1; CMR1) agonist. TRPM8 agonists induce a cooling sensation in sensory neurons and produce profound, mechanistically novel analgesia in chronic pain states such as neuropathic pain.
WS-12 is a menthol derivative, that shows a specific binding affinity towards TRPM8 (transient receptor potential cation channel subfamily M member 8) receptor. TRPM8 is associated with prostate cancer and thus, WS-12 might be useful in reducing the progression of cancer.
 
SML0758   WS3 ≥98% (HPLC) WS3 is a non-cell specific proliferative molecule, thought to act primarily through modulating the activity of ErbB3-binding protein 1 (EBP1) also known as proliferation-associated protein 2G4 (PA2G4), an RNA-binding protein that is involved in growth regulation and inhibition. It may alsohae some activity through the I?B kinase pathway. WS3 was initially found to be a proliferative molecule for β-cells, but more recently found to mediate proliferation of primary retinal pigment epithelial cells. After W3 removal, the retinal cells differentiated into a functional monolayer and remained functional in vivo, preserving vision when they were transplanted into RCS rats used as a model of retinal degeneration.
 
SML0757   WS6 ≥98% (HPLC) WS6 is an inducer of β cell proliferation, thought to act primarily through modulating the activities of the IKB kinase pathway and ErbB3-binding protein 1 (EBP1) also known as proliferation-associated protein 2G4 (PA2G4), an RNA-binding protein that is involved in growth regulation and inhibition.
WS6 is an inducer of β cell proliferation, thought to act primarily through modulating the activities of the IKB kinase pathway and ErbB3-binding protein 1 (EBP1). WS6 is also known to stimulate human ɑ cell proliferation. WS6 does not affect β cell differentiation, as no alteration in the number of insulin producing β cells is observed
 
SML1179 WWL113 ≥98% (HPLC) WWL113 is an inhibitor of mouse Carboxylesterase 3 (Ces3) and human CES1 (orthologue of mCes3), serine hydrolases involved in lipolysis in addition to their activities as liver detoxification enzymes. In a recent study, hCES1 activity was found to be increased two-fold in obese individuals and patients with type 2 diabetes compared to lean subjects, and is thought to generate surplus fatty acids that can deposit ectopically in tissues. WWL113 treatment resulted in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance after three weeks of treatment. WWL113 inhibits Ces3 with an IC50 of 120 nM and also the closely related Ces1f with an IC50 of 100 nM. WWL113 inhibits mouse recombinant Ces1, Ces1c, and Abhd6 at 10 μM.
 
SML1180 WWL229 ≥98% (HPLC) WWL229 is a highly selective inhibitor of mouse Carboxylesterase 3 (Ces3) and human CES1 (orthologue of mCes3), serine hydrolases involved in lipolysis in addition to their activities as liver detoxification enzymes. WWL229 inhibits mCes3 with an IC50 of 10 μM, but not Ces1f, ABHD6 or other tested serine hydrolases. In a recent study, hCES1 activity was found to be increased two-fold in obese individuals and patients with type 2 diabetes compared to lean subjects, and is thought to generate surplus fatty acids that can deposit ectopically in tissues. WWL229 inhibits adipocyte basal lipolysis and promotes differentiation and lipid storage in adipocytes.
 
SML1641 WWL70 ≥98% (HPLC) In mice, WWL70 guards against neuropathic pain stimulated by chronic constriction injury. It decreases the inflammatory response in the ipsilateral spinal cord, dorsal root ganglion (DRG) and sciatic nerve. WWL70 is considered as an anti-inflammatory therapeutic agent, that has the ability to prevent the synthesis of PGE2 (prostaglandin E2) and PGE2-G (PGE2-glyceryl ester).
WWL70 is a selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase that acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). It has an IC50 value of 55-70 nM and 90-95% inihibition of ABDH6. WWL70 hs been used in a variety of studies as an ABHD6 antagonist. It was shown to rescue impaired function of mGluR5 signaling, resulting in pain inhibition in arthritic rats. WWL70 was also used to show that ABHD6 is involved in brown adipose function and white adipose browning, and is a potential therapeutic target for obesity and type 2 diabetes.
 
C7081 WY-14643 Selective PPARα agonist.
human ... PPARA(5465), PPARD(5467), PPARG(5468)
mouse ... Ppara(19013)
rat ... Ppara(25747)
PZ0321   WYE-125132 ≥97% (HPLC) WYE-125132 (WYE-132) is a highly potent, ATP-competitive, and specific inhibitor of mTOR with an IC50 value of 0.19 nM. Unlike rapamycin, which ihibits mTOR through allosteric binding to mTOR complex 1 (mTORC1) only, WYE-132 inhibits both mTORC1 and mTORC2. WYE-125132 is >5000-fold selective for mTOR vs. phosphoinositide 3-kinase (PI3K). WYE-132 induced apoptosis in a variety of cancer lines including LNCap prostate cells and H1975 lung cancer cells. WYE-132 also inhibited ovarian cancer cell growth.
 
SML1168 WZ4002 ≥98% (HPLC) WZ4002 is an irreversible inhibitor of the gatekeeper EGFR-T790M mutation that binds to the active conformation of the EGFR kinase forming a covalent bond with Cys 797.
WZ4002 is effective in the treatment of lung adenocarcinomas due to EGFR (epidermal growth factor receptor) mutations.
 
SML1445 WZ4003 ≥98% (HPLC) WZ4003 helps to repress the migration of cells. It also prevents cell proliferation.
WZ4003 is a potent and selective inhibitor of NUAK1 and NUAK2 kinases, members of the AMPK family that are that are activated by the LKB1 (liver kinase B1) tumour suppressor kinase and involved in development and proliferation. WZ4003 has an IC50 of 20 nM for NUAK1 and an IC50 of 100 nM for NUAK2 without significant inhibition of 139 other kinases tested, including ten AMPK-related kinase family members. Treatment with WZ4003 was found to suppress proliferation, restricting cells from entering into mitosis.
 
SML0088 WZ811 ≥98% (HPLC) WZ811 is a potent, specific antagonist of CXCR4 (IC50 = 0.3 nM). WZ811 blocks SDF-1 mediated changes in cellular cAMP levels in U87 glioma cells (IC50 = 1.2 nM) and Matirgel infiltration of MDA-MB-231 cells (IC50 = 5.2 nM).
 
SML0621 WZB-117 ≥98% (HPLC) WBZ 117 is an inhibitor of basal glucose transport in H1299 lung and other cancer cells.
WZB-117 is an irreversible inhibitor. In cancer cells, WZB-117 prevents cell growth by stimulating apoptosis in any glucose concentration. It targets self-renewal and tumor-initiating capacity in cancer stem cells.